The agency further noted that while full FDA-approved indication is presented at the bottom of the ads, that is not enough to correct the overall misleading impression created by these claims. FDA issued another untitled letter to Amneal for misleading ads in its patient brochures for Alymsys injection for intravenous use
Common Scenarios Where GLOW Can Be Considered A clinician may consider a protocol like GLOW in scenarios such as: tendinopathy that improves but never resolves recurrent sprains and ligament strains joint capsule irritation with persistent instability symptoms slow recovery after repetitive strain from training or work post-procedure remodeling support after prolotherapy or PRP Candidate selection matters
For individuals with a diagnosed B12 deficiency or impaired absorption, the dosage for B12 injections is significantly higher to replenish stores and manage symptoms
Unlike fat-soluble vitamins, it is easily flushed out of the body, making it hard to reach toxic levels
Transcend provides batch-specific COAs showing 98-99%+ purity for most products, matching competitor claims but raising questions about testing consistency across all batches versus selective testing of best-performing samples, whether customers receive the exact batch tested, and if testing frequency justifies premium pricing over vendors with identical COA results
Determining the appropriate dosage of cagrlintide when used alongside tirzepatide requires careful consideration of individual patient factors, including tolerance, response, and any side effects